~~<i id='7317A29D86'><strike id='7317A29D86'><tt id='7317A29D86'><pre id='7317A29D86'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

Wikipedia

author：entertainment 2025-09-02 08:22:52 - browse：64768

Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board.

At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.

The outcome is a setback for Sarissa, which owns 8.5% of Alkermes and is run by activist investor Alex Denner. Sarissa has accused Alkermes executives of mismanaging the business and destroying shareholder value.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： UnitedHealth, Optum discontinue NaviHealth name

entertainment

hotspot

Wikipedia

focus

leisure time

AdobeRecently,dementiavillageshavegainedpopularityinEuropeandAustraliaasanall-in-onesolutiontocaring

WSS

Smaller biotechs seek to piggyback on weight loss drug boom

Abortion pill Supreme Court ruling could impact entire drug industry

Roche subsidiary Foundation Medicine opens new headquarters

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Merck, Daiichi strike cancer drug pact worth up to $22 billion

focus

Wikipedia

entertainment

DIEP, the 'gold standard' of breast reconstruction, is under threat

The Readout: Lenmeldy, GLP

Trump demands the U.S. pay no more for drugs than other countries … again

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

New air purifier tech could be key to improving indoor air quality

Food as medicine: Medically tailored meals may get standardized

Activists slam private health insurers over coverage restrictions

Why a market frenzy over new weight loss drugs defies logic

23andMe had bad news about my health. I wish a person had delivered it

Readout LOUD podcast: mifepristone case, GLP

hotspot

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

There's no autism epidemic. It's an autism diagnosis epidemic

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Is there really a nursing shortage in the U.S.?

Roche acquires Telavant from Roivant, adding experimental IBD treatment

The Readout: Lenmeldy, GLP

Wikipedia

focus

leisure time

leisure time